Naloxone: Nursing Drug Guide, Re-sedation & NCLEX Review

Naloxone is supplied as injectable solutions, prefilled auto-injectors, and intranasal devices. Concentrations and devices are not interchangeable—always match the product in hand to the order and protocol.

Common names include Narcan (intranasal naloxone hydrochloride), Evzio and other auto-injector systems, and numerous generic naloxone hydrochloride injection products (classically 0.4 mg/mL for IV, IM, or SC use). Institutional kits and community take-home programs may use different routes; verify training for each device.

Naloxone is an opioid antagonist used to reverse life-threatening opioid-induced respiratory depression and to diagnose suspected acute opioid overdosage. Nurses administer it in emergency departments, post-anesthesia units, med-surg floors after opioid events, community outreach programs, and anywhere opioids and sedation overlap.

↔On a small screen, swipe or scroll sideways to see the full table.

Naloxone competes at mu, kappa, and sigma opioid receptor sites in the central nervous system, with greatest affinity for mu receptors. It prevents or reverses opioid effects including apnea, sedation, and hypotension. In usual doses without concurrent opioids, naloxone has essentially no pharmacologic activity of its own.

IV onset is generally within about two minutes; IM and SC onset are slightly slower but may produce a more prolonged effect. Because naloxone’s duration can be shorter than that of opioids such as morphine, fentanyl, or methadone, respiratory depression may return as the antagonist is metabolized—this mismatch drives repeat dosing and extended observation.

Dosing depends on indication (overdose versus postoperative titration), route, and product concentration. The table reflects naloxone hydrochloride injection, USP (0.4 mg/mL) labeling; intranasal and auto-injector products have separate instructions.

Repeat dosing: Labeling requires continued surveillance and repeat naloxone as necessary when opioid duration exceeds antagonist effect. Supplemental IM doses may produce longer-lasting effect than IV bolus alone.

Intravenous infusion: Labeling allows dilution (e.g., 2 mg in 500 mL NS or D5W = 0.004 mg/mL) with rate titrated to patient response; discard unused mixture after 24 hours.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Confirm clinical picture suggests opioid-related respiratory depression (miosis, sedation, opioid on medication reconciliation, witnessed ingestion) while maintaining airway per labeling
• Ensure bag-mask ventilation, suction, oxygen, and emergency escalation pathway are active—not antagonist alone
• Verify product concentration (0.4 mg/mL versus 1 mg/mL or intranasal 4 mg per device) and calculate mL from ordered mg
• Screen for known opioid dependence or chronic opioid therapy; plan titrated reversal to avoid fulminant withdrawal when possible
• Review concurrent sedatives; naloxone does not reverse benzodiazepine or alcohol respiratory depression

Contraindications

• Known hypersensitivity to naloxone hydrochloride or formulation ingredients

Important limitations and interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Routes: Reviewed naloxone hydrochloride injection may be given IV, IM, or SC; IV is recommended in emergencies for fastest onset. Intranasal products are administered per device labeling—not as interchangeable mL draw-up from vials.

• Inspect solution for particulate matter and discoloration; protect injectable products from light per labeling
• Administer IV push in overdose when vascular access exists; use IV medication administration safety checks for mg/mL
• When smaller pediatric or postoperative doses are required, discard unused single-dose vial contents per labeling
• Do not mix with alkaline solutions or add other drugs without compatibility verification
• Document time, dose (mg and mL), route, response (RR, SpO₂, arousal), and repeat doses

• Improved respiratory rate and depth; increased arousal and verbal responsiveness
• Rising SpO₂ on pulse oximetry with effective ventilation (confirm waveform and probe placement)
• Reversal of excessive sedation without necessarily eliminating all analgesia when titrated postoperatively
• If no improvement after cumulative 10 mg in adult overdose, reconsider non-opioid causes of depression

After initial reversal, the highest-risk window is recurrent respiratory depression—treat re-sedation as an emergency, not a monitoring glitch.

• Return of bradypnea, shallow breathing, or difficulty breathing after transient improvement
• SpO₂ falling again despite supplemental oxygen—reassess ventilation effort, not only liter flow
• Somnolence progressing to unresponsiveness within 30–90 minutes of last naloxone dose (antagonist wearing off)
• Severe agitation, chest pain, pulmonary edema, or seizures after large or rapid reversal—possible withdrawal or cardiovascular stress
• No response to repeated appropriate naloxone—suspect non-opioid toxidrome, airway obstruction, or partial agonist overdose

↔On a small screen, swipe or scroll sideways to see the full table.

Naloxone itself has limited clinical experience with human overdosage. Volunteers receiving 24 mg/70 kg did not demonstrate toxicity in one small study cited in labeling; higher doses in research and stroke trials produced seizures, severe hypertension, and behavioral symptoms.

Naloxone overdose management

• Treat symptomatically in a supervised setting per labeling
• Contact poison control or medical toxicology services per facility protocol and local emergency guidance

Opioid overdose — role of naloxone

Naloxone is the antidote for opioid-induced respiratory depression, not the entire resuscitation. Continue ventilation between doses until spontaneous effort is reliable.

• Naloxone vs naltrexone / nalmefene—different indications (maintenance versus acute reversal); verify drug name on MAR and vial
• 0.4 mg/mL vs 1 mg/mL vs intranasal 4 mg per spray—independent double-check before administration
• mg versus mL—2 mg order from 0.4 mg/mL vial = 5 mL; miscalculation causes under- or overdosing
• Auto-injector vs ampule—community devices may deliver fixed doses unlike ICU syringe titration
• Flumazenil confusion—benzodiazepine reversal does not treat opioid apnea; giving the wrong antidote delays care

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Respiratory rate, depth, pattern, and effort at least every 15 minutes during acute reversal, then per protocol until stable for extended period
• SpO₂, need for supplemental oxygen or bag-mask ventilation, and mental status (sedation scale if used)
• Heart rate and blood pressure—especially postoperative or cardiovascular patients
• Withdrawal signs (agitation, diaphoresis, vomiting, diarrhea) and pain level after postoperative titration
• Time and cumulative dose of naloxone; clock time when re-sedation would be expected based on last dose and opioid involved

Document

• Indication (overdose versus postoperative), product concentration, each dose (mg and mL), route, and patient response
• Airway interventions, oxygen delivery, and who was notified (prescriber, rapid response, toxicology)
• Planned duration of enhanced monitoring and handoff communication about re-sedation risk

• Naloxone can wear off before opioids do—seek urgent care if breathing slows again, extreme sleepiness returns, or lips turn blue
• Take-home naloxone devices require training on intranasal or auto-injector use; replace expired kits per program instructions
• Do not assume one dose guarantees safety—stay with the person and follow local emergency guidance if symptoms recur
• After reversal, withdrawal may feel like severe flu with anxiety—this is a medical issue, not weakness; report to clinicians
• Contact local poison control or toxicology services per facility protocol for overdose questions; avoid mixing opioids with alcohol or sedatives

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. In imminent life-threatening respiratory arrest from suspected opioids, airway support and naloxone per emergency protocol take priority over elective hold rules.

Rehearse NCLEX-style clinical judgment practice for naloxone using a tabbed emergency-department case (MAR, labs, I&O, nursing notes), then work through priority action, cue recognition (SATA), deterioration trends, documentation cloze, and a matrix that sorts expected findings from re-sedation and withdrawal escalation—recognise cues → analyse → prioritise → act → evaluate outcomes when the antagonist wears off before the opioid does.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.